Additionally, factors like adherence to the prescribed dosage, potential side effects, and overall health conditions should be taken into consideration when determining the expected weight loss
NICE guidance recommends regular review of patients taking GLP-1 agonists, typically every 3-6 months, to assess treatment response, side effects, and ongoing appropriateness of therapy
Common bowel-related side effects include: Diarrhea : Reported in approximately 830% of patients, with higher rates typically seen with weight management doses compared to diabetes doses
Ultimately, this pattern of compulsive seeking and consumptiondriven by neurobiological mechanismssignificantly contributes to the perpetuation of obesity [25], posing a challenge for interventions that do not effectively modulate the glycemic and insulinemic responses underlying these mechanisms